Indications:
Pemigatinib is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements, as detected by an FDA-approved test.This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Dosage and Administration
- Confirm the presence of FGFR2 fusion or rearrangement prior to initiating treatment with Pemigatinib.
- The recommended dose is 13.5 mg taken orally once daily for 14 consecutive days, followed by 7 days off therapy. Each treatment cycle is 21 days.
- Continue treatment until disease progression or unacceptable toxicity occurs.
- Swallow tablets whole. Pemigatinib may be taken with or without food.
Specification
4.5 mg per tablet, 28 tablets per box.
Reviews
There are no reviews yet.